# Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

> **NCT00510471** · PHASE2 · TERMINATED · sponsor: **Genitope Corporation**

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** autologous immunoglobulin idiotype-KLH conjugate vaccine

## Key facts

- **NCT ID:** NCT00510471
- **Lead sponsor:** Genitope Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510471, "Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00510471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*